Listen now on:
latest episodes ↓
18 Jan
42 minEP 118: The role of genetics in drug discovery and development with Dr. Matt Nelson
Join Patrick as he welcomes Dr. Matt Nelson, an influential voice in the field of genetics and drug development. Matt is currently the Vice President of Genetics and Genomics at Deerfield Discovery, as well as the CEO of Genscience. Prior to his current roles, Matt spent 15 years at GlaskoSmithKline (GSK) as a Principal Scientific Investigator and the Head of Genetics. Tune in for an interesting discussion on how genetic data has shaped drug discovery and development over the past decade, and what is needed for the next great leap forward.
Aug 4
43 min 49 secEP103: Gene Writing with Tessera Therapeutics CEO, Dr. Mike Severino
Patrick is joined by Dr. Mike Severino, CEO of Tessera Therapeutics and CEO-Partner of Flagship Pioneering. Join us as Mike walks us through Tessera’s approach to treating genetic diseases by rewriting bases, exons, or even whole genes with a novel approach called Gene Writing.
Aug 4
43 min 49 secEP103: Dr. Marco Schmidt, founder and Chief Scientific Officer of BioTx.ai, on how to use artificial intelligence and machine learning in genomics research
0:00 Intro | 0:45 The founding of BioTx.ai | 4:35 How do algorithms for ‘causal inference’ work? | 6:30 Modeling gene interactions for genetic disorders | 8:35 How to predict gene interactions | 10:30 What happens after identifying a potential gene variant or interaction?
Aug 4
43 min 49 secEP104: Assessing the clinical utility of Polygenic Risk Scores in cancer screening with Professor Clare Turnbull
Join Patrick Short and Professor Clare Turnbull, Professor in Translational Cancer Genetics at the Institute of Cancer Research, as they discuss polygenic risk scores and their application in healthcare
Aug 4
43 min 49 secEP103: Gene Writing with Tessera Therapeutics CEO, Dr. Mike Severino
Patrick is joined by Dr. Mike Severino, CEO of Tessera Therapeutics and CEO-Partner of Flagship Pioneering. Join us as Mike walks us through Tessera’s approach to treating genetic diseases by rewriting bases, exons, or even whole genes with a novel approach called Gene Writing.
Aug 4
43 min 49 secEP103: Dr. Marco Schmidt, founder and Chief Scientific Officer of BioTx.ai, on how to use artificial intelligence and machine learning in genomics research
0:00 Intro | 0:45 The founding of BioTx.ai | 4:35 How do algorithms for ‘causal inference’ work? | 6:30 Modeling gene interactions for genetic disorders | 8:35 How to predict gene interactions | 10:30 What happens after identifying a potential gene variant or interaction?
Aug 4
43 min 49 secEP104: Assessing the clinical utility of Polygenic Risk Scores in cancer screening with Professor Clare Turnbull
Join Patrick Short and Professor Clare Turnbull, Professor in Translational Cancer Genetics at the Institute of Cancer Research, as they discuss polygenic risk scores and their application in healthcare
Aug 4
43 min 49 secEP104: Assessing the clinical utility of Polygenic Risk Scores in cancer screening with Professor Clare Turnbull
Join Patrick Short and Professor Clare Turnbull, Professor in Translational Cancer Genetics at the Institute of Cancer Research, as they discuss polygenic risk scores and their application in healthcare
Aug 4
43 min 49 secEP104: Assessing the clinical utility of Polygenic Risk Scores in cancer screening with Professor Clare Turnbull
Join Patrick Short and Professor Clare Turnbull, Professor in Translational Cancer Genetics at the Institute of Cancer Research, as they discuss polygenic risk scores and their application in healthcare
Aug 4
43 min 49 secEP104: Assessing the clinical utility of Polygenic Risk Scores in cancer screening with Professor Clare Turnbull
Join Patrick Short and Professor Clare Turnbull, Professor in Translational Cancer Genetics at the Institute of Cancer Research, as they discuss polygenic risk scores and their application in healthcare
Aug 4
43 min 49 secEP103: Gene Writing with Tessera Therapeutics CEO, Dr. Mike Severino
Patrick is joined by Dr. Mike Severino, CEO of Tessera Therapeutics and CEO-Partner of Flagship Pioneering. Join us as Mike walks us through Tessera’s approach to treating genetic diseases by rewriting bases, exons, or even whole genes with a novel approach called Gene Writing.
Aug 4
43 min 49 secEP104: Assessing the clinical utility of Polygenic Risk Scores in cancer screening with Professor Clare Turnbull
Join Patrick Short and Professor Clare Turnbull, Professor in Translational Cancer Genetics at the Institute of Cancer Research, as they discuss polygenic risk scores and their application in healthcare
Aug 4
43 min 49 secEP104: Assessing the clinical utility of Polygenic Risk Scores in cancer screening with Professor Clare Turnbull
Join Patrick Short and Professor Clare Turnbull, Professor in Translational Cancer Genetics at the Institute of Cancer Research, as they discuss polygenic risk scores and their application in healthcare
Aug 4
43 min 49 secEP103: Gene Writing with Tessera Therapeutics CEO, Dr. Mike Severino
Patrick is joined by Dr. Mike Severino, CEO of Tessera Therapeutics and CEO-Partner of Flagship Pioneering. Join us as Mike walks us through Tessera’s approach to treating genetic diseases by rewriting bases, exons, or even whole genes with a novel approach called Gene Writing.
